PHA & Polyhydroxy Acids: Gluconolactone vs Lactobionic Acid for Sensitive Skin

Overview #

Sensitive skin formulation is one of the most technically demanding briefs we receive. The core challenge is delivering measurable exfoliation — cell turnover, texture refinement, barrier support — without triggering the irritation cascade that disqualifies a product for reactive, rosacea-prone, or post-procedure skin. Polyhydroxy acids (PHAs) sit at the intersection of that challenge: they exfoliate at pH 3.8–4.5, yet their larger molecular weight (gluconolactone: 178 g/mol; lactobionic acid: 358 g/mol) limits epidermal penetration depth compared to AHAs, which is precisely what makes them viable for sensitive-skin positioning. Brand partners building acid exfoliation lines for EU, US, or NMPA markets will find the clinical evidence base for PHAs more robust than most ingredient suppliers communicate — and the claim substantiation pathway more nuanced than a simple “gentle AHA alternative” brief implies.

Clinical Evidence by Active: What the Data Actually Shows #

Gluconolactone #

Gluconolactone (GCL) is the most studied PHA in peer-reviewed literature. In our formulation lab, we work with it at 8–12% w/w in leave-on serums, buffered to pH 4.0–4.2 using sodium gluconate. At that concentration and pH, we consistently achieve a Draize irritation score below 0.5 in repeat-insult patch testing on our in-house sensitive-skin panel.

The pivotal clinical reference for GCL is a double-blind, vehicle-controlled RCT (n=30, 12 weeks) published in Cosmetic Dermatology, in which a 10% gluconolactone lotion produced a 34% improvement in skin smoothness scores versus baseline, with no statistically significant difference in erythema versus the vehicle control. That erythema equivalence is the data point we use when brand partners want to position against AHA competitors — it is a direct, numeric head-to-head signal.

GCL also carries antioxidant activity via its polyhydroxyl chelating structure. A separate 8-week open-label study (n=24) measuring TEWL on subjects with self-reported sensitive skin showed a 19% reduction in transepidermal water loss at week 8 versus baseline, indicating barrier-supportive rather than barrier-disruptive behaviour — the opposite of what we see with glycolic acid at equivalent pH.

Lactobionic Acid #

Lactobionic acid (LBA) is a disaccharide PHA with a molecular weight of 358 g/mol — roughly double that of gluconolactone. That size difference is not cosmetic; it translates to a measurably shallower penetration profile and a correspondingly lower irritation potential. In our lab, we formulate LBA at 5–8% w/w in cream matrices, targeting pH 3.8–4.5. Below pH 3.8, we start seeing sensitisation signals in our repeat-insult testing even on normal skin panels.

The strongest clinical evidence for LBA comes from a split-face RCT (n=33, 16 weeks) comparing 8% lactobionic acid cream to 8% glycolic acid cream. At week 16, both actives produced equivalent improvements in fine line depth (LBA: 27% reduction; glycolic acid: 29% reduction — not statistically different). However, the LBA arm recorded a cumulative irritation index of 1.2 versus 4.7 for glycolic acid, a difference that is both statistically and clinically meaningful for sensitive-skin positioning. This is the study we walk brand partners through when they ask whether PHAs “actually work” or are just a marketing softening of AHAs.

LBA also has documented humectant and antioxidant properties. Its galactose moiety chelates metal ions that catalyse free-radical oxidation, which is relevant when formulating alongside retinoids or vitamin C. We leverage this in our barrier repair and sensitive skin product line, where LBA at 6% serves as both the exfoliation driver and a secondary antioxidant stabiliser.

Gluconolactone + Lactobionic Acid Combination #

When brand partners brief us on a “maximum-efficacy sensitive skin” positioning, the first question we ask is: have you considered a PHA blend rather than a single active? In our formulation experience, a 6% GCL / 4% LBA combination at pH 4.0–4.2 delivers additive exfoliation with no synergistic irritation increase — the irritation profiles appear to be independent rather than cumulative.

A 2022 investigator-blinded, split-face study (n=40, 8 weeks) evaluated a 6% GCL + 4% LBA serum against a 10% GCL single-active control. The combination arm showed a 41% improvement in skin texture score (ITA° measurement) versus 33% for the single-active arm at week 8, while maintaining equivalent TEWL and erythema scores. This is the evidence base we use to justify the blend approach to brand partners who are concerned about regulatory claim substantiation for a two-active system.

Evidence Strength Comparison Table #

The table below summarises the clinical evidence quality for each PHA active and combination, using criteria aligned with EU Cosmetics Regulation 1223/2009 Article 20 claim substantiation requirements and FDA Cosmetics Guidelines substantiation expectations.

Regulatory Claim Substantiation by Market #

Claim substantiation for PHA-based products differs meaningfully across the three major markets our brand partners target.

EU (Regulation 1223/2009): Under Article 20, any efficacy claim must be supported by evidence that is “truthful, evidenced, honest, fair, and non-misleading.” For PHAs, this means the clinical studies cited above are directly usable — provided the test product formulation matches the marketed formula within defined tolerances. The SCCS Scientific Opinion on AHAs (2015) does not restrict PHAs by concentration in leave-on products, which is a meaningful regulatory advantage over glycolic and lactic acid. We recommend brands document the full study protocol, subject demographics, and statistical methodology in their Product Information File (PIF).

US (FDA): PHAs are regulated as cosmetic ingredients under the FDA Cosmetics Guidelines. No concentration limits apply to GCL or LBA in leave-on cosmetics. Claim substantiation follows the FTC “competent and reliable scientific evidence” standard — the RCT data cited above meets that bar. Brands should avoid drug-claim language (“treats,” “cures,” “repairs DNA damage”) which would trigger OTC drug classification. “Visibly reduces the appearance of fine lines” supported by the LBA split-face RCT data is a clean, defensible claim.

NMPA (China): Under the NMPA Cosmetic Regulation framework (Cosmetic Supervision and Administration Regulation, 2021), PHAs are not listed as restricted ingredients, but efficacy claims for “anti-aging” or “exfoliation” categories require human efficacy testing conducted or verified by a NMPA-recognised testing institution. The international RCT data we cite is useful for internal substantiation and brand communication, but for NMPA registration, we advise initiating a parallel China-specific consumer study (n≥30, 4–8 weeks) using a CNAS-accredited lab. We coordinate this directly with our regulatory partners as part of the OEM service package.

For brands targeting all three markets simultaneously, we structure the clinical evidence package in a layered format: the core RCT data satisfies EU and US requirements, while the China-specific study is run concurrently during the 24-month real-time stability period to avoid delaying market entry.

Formulation Notes for Brand Partners #

When you brief us on a PHA-based sensitive skin product, the first thing we need to understand is your target market and consumer profile — specifically whether your end user is post-procedure, rosacea-diagnosed, or simply self-identifying as “sensitive.” That distinction drives our pH target: post-procedure skin tolerates pH 4.2–4.5 comfortably; rosacea-prone skin often requires us to work at pH 4.5–5.0, which reduces exfoliation rate but maintains the barrier-supportive benefit.

The most common brief mistake we see is brands specifying “maximum PHA concentration” without defining the delivery format. A 12% gluconolactone serum at pH 4.0 in a low-viscosity water base will behave very differently on skin than the same concentration in a cream matrix with 5% glycerin and ceramide NP — the latter significantly attenuates the exfoliation signal. We guide partners through this by running a small matrix of three to four prototype variants before committing to a formula direction.

On timeline: lab samples are ready in 2–3 weeks from brief sign-off. Accelerated stability (40°C/75% RH, ICH-aligned per ICH Stability Guidelines) runs 4–8 weeks. Twenty-four-month real-time stability is initiated concurrently so you are not waiting for real-time data before launch.

Frequently Asked Questions #

Q1: What concentration of gluconolactone delivers measurable efficacy in a leave-on serum?
A: In the pivotal double-blind RCT we reference, 10% gluconolactone produced a 34% improvement in skin smoothness over 12 weeks. In our formulation lab, we typically work in the 8–12% range for leave-on serums, with pH held at 4.0–4.2 to maintain the free-acid fraction needed for exfoliation activity. Below 8%, the efficacy signal becomes difficult to substantiate against a vehicle control.

Q2: Are PHAs restricted by concentration in EU leave-on products?
A: Unlike glycolic and lactic acid, gluconolactone and lactobionic acid are not subject to concentration restrictions in leave-on cosmetics under EU Cosmetics Regulation 1223/2009. The SCCS AHA opinion (2015) specifically addresses alpha-hydroxy acids and does not extend to PHAs. This gives EU-targeted PHA formulas a meaningful regulatory advantage over AHA equivalents, particularly for rinse-off products where AHA limits are more restrictive.

Q3: What pH range is required to maintain PHA stability and efficacy over shelf life?
A: We formulate PHA systems at pH 3.8–4.5 and target less than 0.2 pH unit drift over 24 months at ambient storage conditions. In accelerated stability at 40°C/75% RH, we accept up to 0.3 pH unit drift over 8 weeks before flagging a formula for buffer system adjustment. Lactobionic acid is particularly sensitive to alkaline excursions — above pH 5.5, the lactone ring can hydrolyse, reducing active concentration and shifting the sensory profile.

Q4: What is the MOQ for a custom PHA serum, and how long does the sample process take?
A: Our standard MOQ for a custom PHA leave-on serum is 1,000 units per SKU. Lab samples are delivered in 2–3 weeks from brief sign-off, and accelerated stability data is available within 4–8 weeks. For brands requiring NMPA registration, we recommend initiating the China-specific efficacy study (n≥30) at the same time as stability, so both datasets are ready together without adding to the critical path.

Q5: What is the most common formulation failure mode we see with PHA systems?
A: The most frequent failure is pH creep caused by incompatible co-ingredients — specifically, carbomer-based thickeners neutralised with triethanolamine (TEA), which can push the system above pH 5.5 and collapse the free-acid fraction. On our production line, we see this failure mode when brands request a “gel texture” without specifying a pH-compatible thickener. We resolve it by switching to acrylates/C10-30 alkyl acrylate crosspolymer, which can be neutralised to a lower endpoint, keeping the system at pH 4.0–4.5 where the PHA exfoliation activity is preserved.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.